Forte Biosciences Inc. (FBRX)

3.40
0.20 5.60
NASDAQ
Prev Close 3.60
Open 3.55
Day Low/High 3.05 / 3.55
52 Wk Low/High 3.32 / 53.99
Volume 2.54M
Exchange NASDAQ
Shares Outstanding 14.08B
Market Cap 48.08M
P/E Ratio N/A
Div & Yield N.A. (N.A)

There are plenty of small-caps that have finally bounced and are now consolidating.

Negative sentiment in small-caps and biotech has become extreme and the gap-down open this morning was needed to wash out weak holders.

With breadth negative and the indexes up, here's the investing trap that could get you if you're not careful.

The rotational action is dominating the market, and that means that the individual merits of stocks don't matter.

The end of the quarter means a new round of quarterly reports is near, so it pays to keep an eye on favorite names.

Forte Biosciences is in free fall right now. Here's how I'm playing it.

The tricky part is that sector strength is shifting fast.

This is a nice-looking uptrend right now, and I see no reason to start anticipating major problems.

Here are names that I'm slowly accumulating right now.

Stocks with good charts, good fundamentals, and good stories are attracting buyers.

It's fun to watch the wild action, but it's not healthy for the overall market.

Here are some biotech and gaming names I am watching as these sectors begin to rotate.

Of 56 recent ARKK buys, only two are trading in positive territory Wednesday.

Small-caps look like they may be near the end of a two-month-long correction.

Quite a few stocks are fading right now -- not due to poor fundamentals, but due to lack of buying interest.

Study those charts and be ready to act as things develop.

Forte's sole clinic candidate is FB-401 for the treatment of atopic dermatitis, which is the scientific name for eczema.

While I remain quite bullish, I am trying to strategize a bit to deal with whatever might hide in the waning days of the year.

As this healthy bounce boosts the market, I'm seeing opportunities in these special purpose acquisition companies.

I'm Looking for Some Mild Pullbacks to Create Another Round of Setups

I'm Looking for Some Mild Pullbacks to Create Another Round of Setups

There are plenty of small-caps that have finally bounced and are now consolidating.

Watching This Classic Bottoming Action

Watching This Classic Bottoming Action

Negative sentiment in small-caps and biotech has become extreme and the gap-down open this morning was needed to wash out weak holders.

Don't Fall for This Easy Trading Mistake

Don't Fall for This Easy Trading Mistake

With breadth negative and the indexes up, here's the investing trap that could get you if you're not careful.

There Isn't Any Good Speculative Stock Picking Right Now

There Isn't Any Good Speculative Stock Picking Right Now

The rotational action is dominating the market, and that means that the individual merits of stocks don't matter.

It's Time for a Bit of Repositioning as Another Earnings Season Approaches

It's Time for a Bit of Repositioning as Another Earnings Season Approaches

The end of the quarter means a new round of quarterly reports is near, so it pays to keep an eye on favorite names.

Catching a Falling Knife

Catching a Falling Knife

Forte Biosciences is in free fall right now. Here's how I'm playing it.

Stock Picking Remains the Name of the Game

Stock Picking Remains the Name of the Game

The tricky part is that sector strength is shifting fast.

A Little Rest Friday Is Exactly What's Needed to Keep the Indices Running Higher

A Little Rest Friday Is Exactly What's Needed to Keep the Indices Running Higher

This is a nice-looking uptrend right now, and I see no reason to start anticipating major problems.

Sluggish Traders Face an Out-of-Breadth Market, but I've Got 3 Ideas

Sluggish Traders Face an Out-of-Breadth Market, but I've Got 3 Ideas

Here are names that I'm slowly accumulating right now.

Focus on the Price Action, and Avoid the Perma-Pessimists

Focus on the Price Action, and Avoid the Perma-Pessimists

Stocks with good charts, good fundamentals, and good stories are attracting buyers.

Market Moves Past the Memes

Market Moves Past the Memes

It's fun to watch the wild action, but it's not healthy for the overall market.

Long-Suffering Biotech May Be Hitting a Bottom

Long-Suffering Biotech May Be Hitting a Bottom

Here are some biotech and gaming names I am watching as these sectors begin to rotate.

Biotechs Are One of the Few Positives in This Ugly Market

Biotechs Are One of the Few Positives in This Ugly Market

Of 56 recent ARKK buys, only two are trading in positive territory Wednesday.

3 Names I'm Adding Today

3 Names I'm Adding Today

Small-caps look like they may be near the end of a two-month-long correction.

16 Biotechs I Like Even as a Lack of Liquidity Is Hurting the Market

16 Biotechs I Like Even as a Lack of Liquidity Is Hurting the Market

Quite a few stocks are fading right now -- not due to poor fundamentals, but due to lack of buying interest.

Profit-Taking Is Kicking In: Here Are Some Names on My Shopping List

Profit-Taking Is Kicking In: Here Are Some Names on My Shopping List

Study those charts and be ready to act as things develop.

A Top Biotechnology Play for 2021

A Top Biotechnology Play for 2021

Forte's sole clinic candidate is FB-401 for the treatment of atopic dermatitis, which is the scientific name for eczema.

My Trading Plan as We Wrap Up the Year

My Trading Plan as We Wrap Up the Year

While I remain quite bullish, I am trying to strategize a bit to deal with whatever might hide in the waning days of the year.

Here's Where I'm Seeing Solid Breakouts

Here's Where I'm Seeing Solid Breakouts

As this healthy bounce boosts the market, I'm seeing opportunities in these special purpose acquisition companies.